Recurrent/Metastatic HNSCC
Showing 1 - 25 of >10,000
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) Trial in Pittsburgh (Pembrolizumab, Carboplatin,
Not yet recruiting
- Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
- Pembrolizumab
- +2 more
-
Pittsburgh, PennsylvaniaUPMC Hillman Cancer Center
Sep 18, 2023
Head Neck Cancer Trial in Cincinnati, Columbus (Niraparib, Dostarlimab)
Active, not recruiting
- Head and Neck Cancer
-
Cincinnati, OhioUniversity of Cincinnati Medical Center
Jan 31, 2023
Head Neck Cancer, Squamous Cell Carcinoma of the Head and Neck Trial in La Jolla (Ibrutinib 560mg PO daily (Imbruvica),
Active, not recruiting
- Head and Neck Cancer
- Squamous Cell Carcinoma of the Head and Neck
- Ibrutinib 560mg PO daily (Imbruvica)
- +2 more
-
La Jolla, CaliforniaUCSD Moores Cancer Center
Jan 11, 2023
Head and Neck Squamous Cell Carcinoma Trial (TTI-101, Pembrolizumab)
Not yet recruiting
- Head and Neck Squamous Cell Carcinoma
- (no location specified)
Dec 20, 2022
Recurrent Head Neck Cancer, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Carcinoma Trial in Saint
Not yet recruiting
- Recurrent Head and Neck Cancer
- +5 more
-
Saint Louis, MissouriWashington University School of Medicine
Jul 30, 2023
Metastatic Head Neck Cancer, Recurrent Head Neck Cancer Trial in Worldwide (Bempegaldesleukin, Pembrolizumab)
Terminated
- Metastatic Head and Neck Cancer
- Recurrent Head and Neck Cancer
-
Omaha, Nebraska
- +3 more
Dec 16, 2022
Head Neck Cancer Trial in Tyler (Buparlisib & Paclitaxel)
Recruiting
- Head and Neck Cancer
- Buparlisib & Paclitaxel
-
Tyler, TexasHope Cancer Center, UT Health East Texas
Aug 11, 2022
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Trial in Shanghai (Dalpiciclib+cetuximab)
Recruiting
- Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
-
Shanghai, Shanghai, Chinathe Ninth People's Hospital Affiliated to Shanghai Jiao Tong Uni
Feb 9, 2023
Head and Neck Squamous Cell Carcinoma Trial in Candiolo (inulin, Pembrolizumab, Nivolumab)
Recruiting
- Head and Neck Squamous Cell Carcinoma
- inulin
- +2 more
-
Candiolo, Turin, ItalyFondazione del Piemonte per l'Oncologia-IRCCS Candiolo
Apr 7, 2023
Recurrent Head Neck Cancer, Head Neck Cancer, Head and Neck Tumors Trial in Cincinnati (Durvalumab, Cetuximab)
Active, not recruiting
- Recurrent Head and Neck Cancer
- +3 more
-
Cincinnati, OhioUC Health
Oct 3, 2022
Head and Neck Squamous Cell Carcinoma Trial in France, Germany, Spain (Cisplatin, 5-Fluorouracile, Docetaxel)
Completed
- Head and Neck Squamous Cell Carcinoma
- Cisplatin
- +4 more
-
Avignon, France
- +16 more
Aug 22, 2022
HPV-Related Squamous Cell Carcinoma, HNSCC Trial in London (VB10.16, Pembrolizumab)
Not yet recruiting
- HPV-Related Squamous Cell Carcinoma
- HNSCC
- VB10.16
- Pembrolizumab
-
London, United KingdomEast and North Hertfordshire NHS Trust Mount Vernon Hospital
Aug 24, 2023
Gastroesophageal Junction (GEJ) Cancers, Advanced HNSCC Trial run by the NCI (N-803, Pembrolizumab, PD-L1 t-haNK)
Recruiting
- Gastroesophageal Junction (GEJ) Cancers
- Advanced HNSCC
- N-803
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 26, 2023
Head and Neck Squamous Cell Carcinoma Trial (pembrolizumab)
Completed
- Head and Neck Squamous Cell Carcinoma
- pembrolizumab
- (no location specified)
Jun 23, 2022
Head and Neck Squamous Cell Carcinoma (HNSCC) Trial in Seoul (Nivolumab)
Active, not recruiting
- Head and Neck Squamous Cell Carcinoma (HNSCC)
-
Seoul, Korea, Republic ofYonsei Severance Hospital
Jan 27, 2022
Head and Neck Tumors Trial in France (Atezolizumab, Bevacizumab)
Active, not recruiting
- Head and Neck Neoplasms
-
Lyon, France
- +6 more
May 16, 2022
Head and Neck Squamous Cell Carcinoma, Head Neck Cancer, Head Cancer Trial in United States (IK-175 + nivolumab)
Not yet recruiting
- Head and Neck Squamous Cell Carcinoma
- +5 more
- IK-175 + nivolumab
-
Chicago, Illinois
- +3 more
Jul 26, 2022
Head and Neck Squamous Cell Carcinoma Trial in Shanghai (SI-B001, Paclitaxel)
Recruiting
- Head and Neck Squamous Cell Carcinoma
-
Shanghai, Shanghai, ChinaShanghai Oriental Hospital
Mar 3, 2022
Head and Neck Squamous Cell Carcinoma Trial in Shanghai (SI-B001)
Recruiting
- Head and Neck Squamous Cell Carcinoma
-
Shanghai, Shanghai, ChinaShanghai Oriental Hospital
Dec 16, 2021